Pre-Market Review: Delcath Systems Inc., BioMarin Pharma Inc., Insmed Inc.,
and Akorn Inc.
Editor Note: For more information about this release, please scroll to bottom.
LONDON, November 15, 2013
LONDON, November 15, 2013 /PRNewswire/ --
On Thursday, November 14, 2013, all three indexes of the US equity market
posted gains. The S&P 500 ended the day at 1,790.62, up 0.48%; the Dow Jones
Industrial Average closed at 15,876.22, up 0.35%; and the NASDAQ Composite
finished at 3,972.74, up 0.18%. Shares in the healthcare sector mostly ended
on a lower note, even as the broader market posted gains. The major movers in
the sector included Delcath Systems Inc. (NASDAQ: DCTH), BioMarin
Pharmaceutical Inc. (NASDAQ: BMRN), Insmed Inc. (NASDAQ: INSM), and Akorn Inc.
(NASDAQ: AKRX). AAAResearchReports.com initiated preliminary technical
research on DCTH, BMRN, INSM, and AKRX. These free reports are accessible by
signing today at:
On Thursday, shares in Delcath Systems Inc. fell by 0.76%, even as the broader
market posted gains. The company's shares closed the day at $0.30, after
trading between $0.30 and $0.31. A total of 1.38 million shares were traded,
which below the daily average volume 2.71 million. The company's shares have
fallen by 0.33% in the previous three trading sessions, underperforming the
S&P 500, which has gained 1.06% during the same period. Furthermore, Delcath
Systems Inc.'s stock is trading below its 50-day and 200-day moving averages
of $0.37 and $0.77, respectively. The free technical analysis on DCTH is
available by signing up at:
Shares in BioMarin Pharmaceutical Inc. edged higher on Thursday, tracking
gains in the broader market. The company's shares closed the day 0.22% higher
at $64.33, after vacillating between $63.88 and $65.48. A total of 2.00
million shares were traded, which is above the daily average volume of 1.79
million. The company's shares have gained 3.76% in the previous three trading
sessions outperforming the S&P 500, which has gained 1.06% during the same
period. Further, BioMarin Pharmaceutical Inc.'s stock is trading above its
200-day moving average of $63.51. Register now to download free research on
Insmed Inc.'s stock fluctuated between $15.13 and $15.72 before ending the
Thursday's session 1.55% lower at $15.24. A total of 0.32 million shares were
traded, which is below the daily average volume of 0.65 million. Despite
Thursday's pullback, the company's shares have surged 16.87% in the last one
month and 40.20% in the previous three months, outperforming the S&P 500,
which has advanced 4.71% and 6.24% during the respective periods.
Additionally, Insmed Inc.'s stock is trading above its 50-day and 200-day
moving averages of $14.88 and $10.96, respectively. A free report on INSM can
be accessed by registering at:
On Thursday, Akorn Inc.'s stock ended the day 0.97% lower at $21.50 after
hitting a new 52-week high of $22.07. A total of 0.71 million shares were
traded, which is below the daily average volume of 0.75 million. Despite
Thursday's decline, the company's shares have gained 7.77% in the last one
month and 34.46% in the previous three months, outperforming the S&P 500,
which has advanced 4.71% and 6.24% during the respective periods. Moreover,
Akorn Inc.'s stock is trading above its 50-day and 200-day moving averages of
$19.90 and $15.66, respectively. Register with AAA Research Reports and
download research on AKRX for free at:
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
only human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
SOURCE AAA Research Reports
Contact: Peter F. Jones; Phone #: + 1 (646) 396-9126; Email ID:
Press spacebar to pause and continue. Press esc to stop.